FEIYANG GROUP (01901) announced an annual net loss of RMB 30.55 million, a decrease of 44.28% year-on-year.

07:53 31/03/2026

Feiyang Group (01901) released its annual performance results for the year ending on December 31, 2025. The group's revenue was 783 million yuan, an increase of 9.39% year-on-year; gross profit was 50.57 million yuan; net loss was 30.55 million yuan, a decrease of 44.28% year-on-year; basic loss per share was 4.4 fen.

FEIYANG GROUP (01901) announced its annual performance for the year ending December 31, 2025. The Group's revenue was 783 million yuan, a year-on-year increase of 9.39%; gross profit was 50.57 million yuan; net loss was 30.55 million yuan, a year-on-year decrease of 44.28%; basic loss per share was 4.4 cents.

China Glass (03300) announced a net loss attributable to equity shareholders of approximately RMB 4.893 billion in 2025, representing an increase of about 4.58 times year-on-year.

CITIC SEC: The value of energy security is highlighted, and public utilities are expected to benefit from reevaluation

SSY GROUP(02005): Upatinib has been approved by the China Food and Drug Administration for registration as an active pharmaceutical ingredient for use in marketed preparations.

China Glass (03300) announced a net loss attributable to equity shareholders of approximately RMB 4.893 billion in 2025, representing an increase of about 4.58 times year-on-year.

CITIC SEC: The value of energy security is highlighted, and public utilities are expected to benefit from reevaluation

SSY GROUP(02005): Upatinib has been approved by the China Food and Drug Administration for registration as an active pharmaceutical ingredient for use in marketed preparations.